Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
Background - Bevacizumab, the anti-vascular endothelial growth factor agent, provides clinical benefit when combined with platinum-based chemotherapy in first-line advanced non-small-cell lung cancer. We report the final overall survival (OS) analysis from the phase III AVAiL trial. - Patients and m...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
September 2010
|
| In: |
Annals of oncology
Year: 2010, Jahrgang: 21, Heft: 9, Pages: 1804-1809 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdq020 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/annonc/mdq020 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0923753419400471 
|
| Verfasserangaben: | M. Reck, J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, N. Moore, C. Manegold & BO17704 Study Group |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 184517898X | ||
| 003 | DE-627 | ||
| 005 | 20230710134546.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230511s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdq020 |2 doi | |
| 035 | |a (DE-627)184517898X | ||
| 035 | |a (DE-599)KXP184517898X | ||
| 035 | |a (OCoLC)1389805683 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Reck, Martin |d 1965- |e VerfasserIn |0 (DE-588)137678711 |0 (DE-627)594837413 |0 (DE-576)30483873X |4 aut | |
| 245 | 1 | 0 | |a Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer |b results from a randomised phase III trial (AVAiL) |c M. Reck, J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, N. Moore, C. Manegold & BO17704 Study Group |
| 264 | 1 | |c September 2010 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Elektronische Reproduktion der Druckausgabe | ||
| 500 | |a Gesehen am 11.05.2023 | ||
| 520 | |a Background - Bevacizumab, the anti-vascular endothelial growth factor agent, provides clinical benefit when combined with platinum-based chemotherapy in first-line advanced non-small-cell lung cancer. We report the final overall survival (OS) analysis from the phase III AVAiL trial. - Patients and methods - Patients (n=1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n=345), bevacizumab 15 mg/kg (n=351) or placebo (n=347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. - Results - Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64-0.87), P=0.0003 and 0.85 (0.73-1.00), P=0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78-1.11), P=0.420 and 1.03 (0.86-1.23), P=0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (∼62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. - Conclusions - Final analysis of AVAiL confirms the efficacy of bevacizumab when combined with cisplatin-gemcitabine. The PFS benefit did not translate into a significant OS benefit, possibly due to high use of efficacious second-line therapies. | ||
| 650 | 4 | |a bevacizumab | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a NSCLC | |
| 650 | 4 | |a overall survival | |
| 650 | 4 | |a vascular endothelial growth factor | |
| 700 | 1 | |a von Pawel, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zatloukal, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ramlau, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gorbounova, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hirsh, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Leighl, N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mezger, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Archer, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Moore, N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Manegold, Christian |d 1946-2022 |e VerfasserIn |0 (DE-588)108614913 |0 (DE-627)490287360 |0 (DE-576)289617200 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 21(2010), 9 vom: Sept., Seite 1804-1809 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer results from a randomised phase III trial (AVAiL) |
| 773 | 1 | 8 | |g volume:21 |g year:2010 |g number:9 |g month:09 |g pages:1804-1809 |g extent:6 |a Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer results from a randomised phase III trial (AVAiL) |
| 856 | 4 | 0 | |u https://doi.org/10.1093/annonc/mdq020 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0923753419400471 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230511 | ||
| 993 | |a Article | ||
| 994 | |a 2010 | ||
| 998 | |g 108614913 |a Manegold, Christian |m 108614913:Manegold, Christian |d 60000 |d 61800 |e 60000PM108614913 |e 61800PM108614913 |k 0/60000/ |k 1/60000/61800/ |p 11 |y j | ||
| 999 | |a KXP-PPN184517898X |e 4320663284 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Elektronische Reproduktion der Druckausgabe","Gesehen am 11.05.2023"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"184517898X","language":["eng"],"person":[{"roleDisplay":"VerfasserIn","display":"Reck, Martin","role":"aut","family":"Reck","given":"Martin"},{"role":"aut","display":"von Pawel, J.","roleDisplay":"VerfasserIn","given":"J.","family":"von Pawel"},{"given":"P.","family":"Zatloukal","role":"aut","roleDisplay":"VerfasserIn","display":"Zatloukal, P."},{"role":"aut","display":"Ramlau, R.","roleDisplay":"VerfasserIn","given":"R.","family":"Ramlau"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Gorbounova, V.","given":"V.","family":"Gorbounova"},{"given":"V.","family":"Hirsh","role":"aut","display":"Hirsh, V.","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Leighl, N.","roleDisplay":"VerfasserIn","given":"N.","family":"Leighl"},{"roleDisplay":"VerfasserIn","display":"Mezger, J.","role":"aut","family":"Mezger","given":"J."},{"given":"V.","family":"Archer","role":"aut","display":"Archer, V.","roleDisplay":"VerfasserIn"},{"display":"Moore, N.","roleDisplay":"VerfasserIn","role":"aut","family":"Moore","given":"N."},{"roleDisplay":"VerfasserIn","display":"Manegold, Christian","role":"aut","family":"Manegold","given":"Christian"}],"title":[{"title_sort":"Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer","title":"Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer","subtitle":"results from a randomised phase III trial (AVAiL)"}],"physDesc":[{"extent":"6 S."}],"relHost":[{"id":{"issn":["1569-8041"],"zdb":["2003498-2"],"eki":["320428796"]},"origin":[{"dateIssuedDisp":"1990-","dateIssuedKey":"1990","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Annals of oncology","title":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology"}],"part":{"year":"2010","pages":"1804-1809","issue":"9","volume":"21","text":"21(2010), 9 vom: Sept., Seite 1804-1809","extent":"6"},"pubHistory":["1.1990 -"],"recId":"320428796","language":["eng"],"corporate":[{"display":"European Society for Medical Oncology","roleDisplay":"Herausgebendes Organ","role":"isb"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"disp":"Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer results from a randomised phase III trial (AVAiL)Annals of oncology"}],"name":{"displayForm":["M. Reck, J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, N. Moore, C. Manegold & BO17704 Study Group"]},"origin":[{"dateIssuedKey":"2010","dateIssuedDisp":"September 2010"}],"id":{"doi":["10.1093/annonc/mdq020"],"eki":["184517898X"]}} | ||
| SRT | |a RECKMARTINOVERALLSUR2010 | ||